We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Long-term Use of Bisphosphonates Lowers Risk of Colorectal Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Bisphosphonates, calcium-regulating drugs that inhibit bone resorption and used in the treatment of hypercalcemia and osteoporosis in humans, have been found to reduce the risk of developing colorectal cancer.

In addition to being used for treatment of osteoporosis, bisphosphonates are also used to treat bone metastases caused by breast cancer, and were recently reported to be associated with a reduced risk of the disease. More...
To see if treatment with bisphosphonates would correlate with reduced risk for other types of cancer, investigators at the Technion--Israel Institute of Technology (Haifa, Israel) evaluated the use of bisphosphonates with the risk for developing colorectal cancer.

Data on the long-term use of bisphosphonates before diagnosis by 1,866 postmenopausal female participants was extracted from the Molecular Epidemiology of Colorectal Cancer (MECC) study, a population-based case-control study in northern Israel.

Results published in the February 14, 2011, online edition of the Journal of Clinical Oncology revealed that the use of bisphosphonates for more than one year before diagnosis, but not for less than one year, was associated with a significantly reduced relative risk of colorectal cancer. This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones.

Overall, the use of oral bisphosphonates for more than one year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.

"We formerly identified a new class of drugs associated with a reduced risk of breast cancer,” said first author Dr. Gad Rennert, professor of medicine at the Technion--Israel Institute of Technology. "And, now, by showing a similar effect on colorectal cancer risk reduction, we can assume that this class of medications has a broad effect - not necessarily limited to a specific cancer site.”

"While the disease is generally caused by bad dietary habits and lack of physical activity, it can possibly be prevented by several medications, such as aspirin and cholesterol-lowering medication of the statins group,” said Dr. Rennert. "And now, we can add bisphosphonates to the list of tools for potential prevention of colorectal cancer.”

Related Links:

Technion-Israel Institute of Technology



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.